What is an amenable mutation?
An amenable mutation is a genetic change or variant that a person may have that is responsive - amenable - to treatment.
The term ‘amenable mutation’ is used to describe certain mutations of the galactosidase alpha gene (GLA), found in people with Fabry disease, which respond to treatment with Galafold (migalastat).
Fabry disease is a rare genetic lysosomal storage disorder that predominantly affects the nervous system, heart and kidneys. It is caused by mutations in the GLA gene, which is needed to make an enzyme that works in lysosomes called alpha-galactosidase A. Alpha-galactosidase A helps to break down and recycle a molecule called globotriaosylceramide, as part of the process to recycle old red blood cells and other cells. If globotriaosylceramide isn’t broken down it accumulates and can damage cells.
Mutations in GLA produce abnormal versions of the alpha-galactosidase A enzyme. Mutations can result in an enzyme with reduced activity, which results in a milder version of Fabry disease, or a complete loss of enzyme activity, which results in a more severe version of the disease.
The most common type of mutation found in people with Fabry disease results in a single amino acid being changed, but mutations that delete part of the GLA gene, insert extra genetic material into the gene, or signal the gene to prematurely stop before alpha-galactosidase is produced are also found.
Galafold works by binding to sites on amenable mutant forms of alpha-galactosidase A, stabilizing it and chaperoning it into lysosomes where it can work. Mutant forms that aren’t responsive to treatment with Galafold are known as nonamenable mutations.
References
- Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430-438. doi:10.1038/gim.2016.122.
- MedlinePlus. GLA gene. [Accessed August 20, 2021]. Available from: https://medlineplus.gov/genetics/gene/gla/.
- Food and Drug Administration (FDA). Galafold. September 2020. [Accessed August 20, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208623s003lbl.pdf.
See also:
Aimovig
Learn about Aimovig (erenumab-aooe) a once-monthly, injectable medication that can be ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Depakote
Depakote is used to treat various types of seizure disorders. Learn about side effects ...
Topamax
Topamax (topiramate) is used to prevent seizures in adults and children and to prevent migraine ...
Emgality
Emgality (galcanezumab-gnlm) is a CGRP antagonist for the preventive treatment of migraine and for ...
Timolol
Timolol is used for angina, heart attack, high blood pressure, migraine, migraine prevention
Valproic acid
Valproic acid is used for bipolar disorder, cluster-tic syndrome, epilepsy, headache ...
Divalproex sodium
Divalproex sodium is used for bipolar disorder, borderline personality disorder, cyclothymic ...
Topiramate
Learn about topiramate, an anticonvulsant used for seizures, migraine prevention, and weight loss ...
Related medical questions
- How much does Galafold cost?
- How is fabrazyme administered/infused?
- How does Fabrazyme enzyme replacement therapy work?
Drug information
- Galafold Information for Consumers
- Galafold prescribing info & package insert (for Health Professionals)
- Side Effects of Galafold (detailed)
Related support groups
- Galafold (2 questions, 3 members)
- Fabry Disease (4 questions, 3 members)